TR200100645T2 - PARP inhibitörleri olarak doymamış hidroksimik asit türevleri. - Google Patents

PARP inhibitörleri olarak doymamış hidroksimik asit türevleri.

Info

Publication number
TR200100645T2
TR200100645T2 TR2001/00645T TR200100645T TR200100645T2 TR 200100645 T2 TR200100645 T2 TR 200100645T2 TR 2001/00645 T TR2001/00645 T TR 2001/00645T TR 200100645 T TR200100645 T TR 200100645T TR 200100645 T2 TR200100645 T2 TR 200100645T2
Authority
TR
Turkey
Prior art keywords
hydroxyimic
acid derivatives
unsaturated
parp inhibitors
compounds
Prior art date
Application number
TR2001/00645T
Other languages
English (en)
Inventor
Literati Peter
S�Megi Balazs
Takacs Kalman
Original Assignee
N-Gene Kutato Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU9802001A external-priority patent/HU9802001D0/hu
Priority claimed from HU9902927A external-priority patent/HUP9902927A3/hu
Application filed by N-Gene Kutato Kft filed Critical N-Gene Kutato Kft
Publication of TR200100645T2 publication Critical patent/TR200100645T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bulusun hedefi, yeni doymamis hidroksimik asit türevleri, bunlarin hazirlanmasi için bir islem ve aktif madde olarak bu bilesikleri içeren farmasötik bilesimlerdir. Yeni bilesikler, degerli farmasötik etkilere sahiptirler; PARP inhibisyonunun neden oldugu hücrelerin enerji yetersizligi ile baglantili durumlarin, diyabet komplikasyonlarinin, kalp ve beynin oksijen yetersizligi durumunun, nörodejeneratif hastaliklarin, otoimmün ve/veya viral hastaliklarin tedavisinde kullanilabilirler.
TR2001/00645T 1998-09-03 1999-09-02 PARP inhibitörleri olarak doymamış hidroksimik asit türevleri. TR200100645T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9802001A HU9802001D0 (en) 1998-09-03 1998-09-03 New unsaturated hydroximic acid derivatives, process for producing them, and pharmaceutical compositions containing them
HU9902927A HUP9902927A3 (en) 1999-08-31 1999-08-31 New unsaturated hydroxym-acid-derivatives, process for their production and medicaments containing them

Publications (1)

Publication Number Publication Date
TR200100645T2 true TR200100645T2 (tr) 2001-06-21

Family

ID=89999161

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00645T TR200100645T2 (tr) 1998-09-03 1999-09-02 PARP inhibitörleri olarak doymamış hidroksimik asit türevleri.

Country Status (25)

Country Link
US (1) US6500823B1 (tr)
EP (1) EP1115697B1 (tr)
JP (1) JP2002524439A (tr)
KR (1) KR100632522B1 (tr)
CN (1) CN1211353C (tr)
AT (1) ATE258916T1 (tr)
AU (1) AU771782B2 (tr)
BR (1) BR9913425A (tr)
CA (1) CA2342898A1 (tr)
CZ (1) CZ2001705A3 (tr)
DE (1) DE69914614T2 (tr)
DK (1) DK1115697T3 (tr)
ES (1) ES2215400T3 (tr)
HK (1) HK1040700A1 (tr)
IL (2) IL141756A0 (tr)
MX (1) MXPA01002315A (tr)
NO (1) NO20011091L (tr)
NZ (1) NZ510933A (tr)
PL (1) PL194275B1 (tr)
PT (1) PT1115697E (tr)
RU (1) RU2220953C2 (tr)
SK (1) SK2532001A3 (tr)
TR (1) TR200100645T2 (tr)
UA (1) UA65635C2 (tr)
WO (1) WO2000014054A1 (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE265998T1 (de) * 2000-03-20 2004-05-15 N Gene Res Lab Inc Propancarbonsäure-amidoxim derivate, ein verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese entahlten
MXPA04000324A (es) * 2001-07-17 2004-07-23 N Gene Res Lab Inc Una combinacion farmaceutica sinergistica para la prevencion o tratamiento de diabetes.
CA2537097A1 (en) * 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
MX2007000142A (es) * 2004-06-30 2007-03-26 Combinatorx Inc Metodos y reactivos para el tratamiento de desordenes metabolicos.
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
WO2018085359A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
CN113354557B (zh) * 2021-06-07 2022-06-28 大连理工大学 一种3-苯基-2-丙烯-1-酮o-正丁基肟的制备方法及应用
KR20240070616A (ko) * 2021-09-28 2024-05-21 제브라 덴마크 에이/에스 옥심 및 gba 관련 질환의 치료에서의 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
HU213421B (en) * 1993-04-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar New basic ethers, pharmaceutical compns. containing the said compds. and process for prepg. them
DK0841924T3 (da) 1995-08-02 2003-02-10 Univ Newcastle Ventures Ltd Benzimidazolforbindelser
DE19756236A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide

Also Published As

Publication number Publication date
NO20011091L (no) 2001-05-02
BR9913425A (pt) 2001-11-27
KR20010085760A (ko) 2001-09-07
PT1115697E (pt) 2004-06-30
HK1040700A1 (en) 2002-06-21
DE69914614T2 (de) 2005-01-05
JP2002524439A (ja) 2002-08-06
EP1115697A1 (en) 2001-07-18
DE69914614D1 (de) 2004-03-11
DK1115697T3 (da) 2004-06-07
EP1115697B1 (en) 2004-02-04
RU2220953C2 (ru) 2004-01-10
ES2215400T3 (es) 2004-10-01
NO20011091D0 (no) 2001-03-02
CA2342898A1 (en) 2000-03-16
KR100632522B1 (ko) 2006-10-09
NZ510933A (en) 2003-01-31
SK2532001A3 (en) 2001-08-06
AU771782B2 (en) 2004-04-01
WO2000014054A1 (en) 2000-03-16
MXPA01002315A (es) 2002-05-08
CN1211353C (zh) 2005-07-20
CN1322193A (zh) 2001-11-14
IL141756A0 (en) 2002-03-10
US6500823B1 (en) 2002-12-31
PL346547A1 (en) 2002-02-11
AU5753799A (en) 2000-03-27
ATE258916T1 (de) 2004-02-15
UA65635C2 (uk) 2004-04-15
IL141756A (en) 2006-08-01
CZ2001705A3 (cs) 2001-08-15
PL194275B1 (pl) 2007-05-31

Similar Documents

Publication Publication Date Title
PT1153024E (pt) 2-amino-6-anilino-purinas e sua utilizacao como medicamentos
TR200100645T2 (tr) PARP inhibitörleri olarak doymamış hidroksimik asit türevleri.
SG47517A1 (en) (1-92-oxo-acetyl)-piperidine-2-carboxylic acid derivatives as multi-drug-resistant cancer cell sensitizers
DK0643775T3 (da) Quinonderivater til forbedring af cellebioenergi
DE59913103D1 (de) Substituierte 4-amino-2-aryl-cyclopenta ädüpyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
TR200103153T2 (tr) Yeni bileşimler
MD1688G2 (ro) Benzotiofen, benzofuran şi indoltiazepinone, oxazepinone şi diazepinone, compoziţie farmaceutică, metodă de inhibare a aderării leucocitelor la celulele endoteliale pentru tratamentul proceselor inflamatorii şi metodă de tratament al mamiferelor infectate cu HIV infecţie .
TR200002506T2 (tr) S ile ikame edilmiş 11beta-benzaldoksim-estra-4,9-dien-karbonik asit tiolesterler, üretimleri için yöntem ve bu bileşimleri içeren farmasötik terkipler.
TR199801229T2 (tr) ''Metalopeptidaz inhibisyon aktivitesini havi tiol türevleri
ES2001703A6 (es) Procedimiento para la preparracion de derrrivados de acidos 2-(2-imidazolin -2-il)- piridin -3- carboxilicos.
IT1276162B1 (it) Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE60006936D1 (de) Substituierte 4-amino-2-aryltetrahydrochinazoline, deren herstellung, deren verwendung und diese enthaltende pharmazeutische zusammenstellungen
TR200101083T2 (tr) (7alfa,17alfa)-17-hidroksi- 7-metil-19-nor-17-pregn-5 (10)-en-20-in-3-on içeren yüksek saflıkta bileşim.
PT82889A (en) Process for the preparation of preventive drugs for elastosis containinvg kojic acid
ES480113A1 (es) Procedimiento para la preparacion de nuevos derivados de 2- iminoimidazolidina.
ATE177424T1 (de) N-substituierte naphthalimide, ihre herstellung und verwendung
TR200101388T2 (tr) Yeni pirimidin türevleri ve bunları hazırlama prosesleri
IL83088A (en) Substituted 3-isoquinolinols,their preparation and pharmaceutical compositions containing them
TR199800195A2 (tr) Sulfonamid-ikame edilmis bilesikler, bunlarin imalat usulü.
DK162440C (da) Pyrazindiazohydroxidforbindelser
DE69614508D1 (de) Thiol derivate mit metallopeptidase inhibierender aktivitat
MX9805168A (es) Derivados de tiol con actividad inhibitoria de la metalopeptidasa (ace-nep).
ES8605584A1 (es) Un procedimiento para preparar foroximitina
ITMI952771A1 (it) Orologio modulare componibile composto da tre parti montate a coppie in maniera simmetrica le parti racchiudono il ad orologeria ed il
MX9503130A (es) Inhibidores de metaloproteinasa, proceso para su preparacion y composiciones farmaceuticas o veterinarias que los contienen.